Rheumatology

Use of Infliximab Biosimilar in Medicare Population Is Low but Growing

July 7th 2020

By Deana Ferreri, PhD

Slow growth of use of biosimilar infliximab in a Medicare fee-for-service population suggests lingering hesitancy on the part of gastroenterologists and patients, particularly when it comes to extrapolation to off-label uses, according to a new study.

Review: Nurses Can Play Key Role in Improving Biosimilar Use

July 7th 2020

By Skylar Jeremias

Article

A review laid out ways for nurses to address patients’ questions on biosimilars in order to help them take on the role of improving utilization rates in cancer treatment.

Remove the Disincentives and Biosimilars Will Flourish, Policy Expert Says

July 7th 2020

By Tony Hagen

Article

Wayne Winegarden, PhD, director of the Center for Medical Economics and Innovation, explains that misaligned incentives are preventing the United States from realizing full benefit from biosimilars.

US Rheumatologists Are Comfortable With Biosimilars, but Still Hesitant to Prescribe

July 4th 2020

By Sonia T. Oskouei, PharmD, BCMAS, DPLA

Article

Cardinal Health Specialty Solutions has produced a Rheumatology Insights report that includes results from a survey of over 100 US-based rheumatologists on their perceptions and experiences with biosimilars in rheumatology thus far.

ACR Supports Continued Use of Telemedicine and Reimbursement Parity After COVID-19 Crisis

July 1st 2020

By Laura Joszt, MA

Article

The widespread adoption of telemedicine during the coronavirus disease 2019 (COVID-19) pandemic, as well as reimbursement parity that was enacted by CMS, should be continued once the public health emergency passes, according to a new position statement by the American College of Rheumatology (ACR).

First Adalimumab Biosimilar Gains Approval in Japan

June 30th 2020

By Tony Hagen

Article

Japanese authorities have given marketing approval for the first adalimumab biosimilar in that country.

IQVIA Rates European Countries on Biosimilar Market Health

June 30th 2020

By Tony Hagen

Article

A new scorecard system developed by IQVIA rates the health and sustainability of biosimilars markets across Europe.

Rheumatologists Still Leery of Biosimilar Use, Study Says

June 30th 2020

By Skylar Jeremias

Article

In surveys conducted in February and March 2020, rheumatologists cited low adoption rates of biosimilars by payers and unfavorable discounts as major reasons why they feel uncomfortable switching prescribing patterns from reference products to biosimilars.

US Oncology's Rifkin Explains Rituximab Uptake

June 29th 2020

By Tony Hagen

Article

The US Oncology Network is pushing to get more biosimilars into utilization, Robert M. Rifkin, MD, told The Center for Biosimilars® in an interview.

CHMP Recommends 5 New Indications for Celltrion's Infliximab

June 29th 2020

By Tony Hagen

Article

Based on clinical studies on dosing, efficacy, and pharmacokinetics, European authorities have recommended Celltrion's subcutaneous infliximab biosimilar (Remsima SC) for 5 new indications.